Company intelligence / Profile preview

Launch Therapeutics

Massachusetts, United Stateslaunchtx.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Launch Therapeutics specializes in accelerating the clinical development and regulatory approval of late-stage drug candidates. The team has overseen more than 396 Phase 3 studies and brought over 95 assets to market. They provide both advisory and hands-on operational execution for biotech/pharma partners, focusing on de-risking pivotal trials and expediting commercialization pathways. One known active program is a Phase 3 trial evaluating PLS240 for secondary hyperparathyroidism in end stage kidney disease patients on hemodialysis.

Therapeutic areas: Nephrology
Modalities: Small moleculeBiologic
Industry: Contract Research Organization

Drug pipeline

1 asset

fluticasone + albuterol

Phase 3

Indications: Asthma

Partnerships

Pathalys Pharma (clinical trial collaboration/sponsorship)

Beyond the preview

Go deeper on Launch Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Launch Therapeutics.

Explore the full profile